Clinical trials: IBM
Inclusion Body Myositis
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Inclusion body myositis (IBM) is the most common late onset acquired muscle disease. Patients develop progressive weakness that may result in the need for assistive devices including a wheelchair.
- Trial name
- NCT00802815
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Refractory Myositis
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
This is a 4 month open trial with TNF-blockade using infliximab (an antibody that blocks TNF) in adult patients with chronic myositis (polymyositis, dermatomyositis, inclusion body myositis) who have persisting muscle weakness…
- Trial name
- NCT00443222
- Testing
- Infliximab
- Sponsor
- Karolinska Institutet
Polymyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids…
- Trial name
- NCT01801917
- Testing
- BAF312
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Weakness
Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms
This study will evaluate whether a dietary supplement, coenzyme Q10 (CoQ10), will improve muscle symptoms, such as muscle aches, pains, cramps, and/or weakness, which are experienced by some individuals who use statin medications.
- Conditions
- Pain, Weakness, Cramps, Myalgia or Myositis Nos
- Trial name
- NCT01032993
- Testing
- Coenzyme Q10
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Catherine Buettner
Inclusion Body Myositis (IBM)
Natalizumab in Inclusion Body Myositis (IBM)
Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death may be a novel treatment for IBM.
- Trial name
- IBM-NAT (NCT02483845)
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Phoenix Neurological Associates, LTD
Inclusion Body Myositis
Phase III Trial of Sirolimus in IBM
The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ transplantation and works by blocking the activity of T effector cells but preserving T regulatory cells, as well as by inducing autophagy…
- Trial name
- NCT04789070
- Testing
- Sirolimus
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 140 people
- Sponsor
- University of Kansas Medical Center
Inclusion Body Myositis
Cell Therapy for IBM by Muscle Injection of ADSVF
Inclusion Body Myositis is a slowly but disabling myopathy, the most frequent in patients over 50 years old. No treatments (in particular immunosuppressive) are known to be efficient.
- Trial name
- ADSVF-in-IBM (NCT05032131)
- Testing
- ADSVF
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris